(Q54718480)

English

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. (English)

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Brian I Rini

1

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Vivian Weinberg

2

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Lawrence Fong

3

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Shauna Conry

4

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Robert M Hershberg

5

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Eric J Small

6

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

language of work or name

0 references

publication date

1 July 2006

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

107

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

1

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

67-74

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21956

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21956

7 January 2021

based on heuristic

inferred from DOI database lookup

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21956

7 January 2021

based on heuristic

inferred from DOI database lookup

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21956

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21956

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21956

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/16736512

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54718480&oldid=1424750635"